About omaveloxo lone
Nrf2 pathway activator
Used for
- Treatment of Friedreich ataxia in adults and adolescents aged 16 years and older.
Usual adult dose
150 mg by mouth once daily, taken on an empty stomach.
Usual dose in children
Not established for children younger than 16 years.
Common side effects
- Increased liver enzymes
- Headache
- Nausea
- Abdominal pain or diarrhea
Important warnings
- Monitor liver enzymes before and during treatment.
- May cause elevated B-type natriuretic peptide; assess for heart problems if symptoms occur.
- Avoid use with strong or moderate CYP3A4 inhibitors or inducers.
- Capsules must be swallowed whole; do not open or crush.
Pregnancy
Human pregnancy data are limited; potential fetal harm is uncertain.
Breastfeeding
Unknown whether omaveloxolone passes into breast milk; effects on infants are uncertain.
Interactions
- CYP3A4 inhibitors can increase omaveloxolone exposure.
- CYP3A4 inducers can reduce omaveloxolone exposure.
- Omaveloxolone can reduce effectiveness of hormonal contraceptives.
- It may affect medicines transported by BCRP or OATP1B1.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.